Print 18 December 2013
Dr. Deepak Bhatt Joins Key Advisory Group As Regado Advances Phase 3 REGULATE-PCI Study
BASKING RIDGE, N.J., Dec. 17, 2013 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that Deepak L. Bhatt, M.D., M.P.H., F.A.C.C., F.A.H.A., has joined the Company's Medical Advisory Board. Regado will benefit from Dr. Bhatt's expertise in cardiovascular intervention and years of experience leading international cardiovascular clinical trials, as the Company actively enrolls patients in its Phase 3 REGULATE-PCI study and positions REG-1 as a potential standard of care for anticoagulant use in percutaneous coronary intervention procedures.
Dr. Bhatt commented, "I have always been attracted to advanced technologies with applications in cardiovascular intervention because of the potential to improve patient care. I look forward to exploring the new possibilities for managing patients safely and effectively through technological advances in controllable drug systems."
David J. Mazzo, Ph.D., Chief Executive Officer of Regado Biosciences, stated, "Dr. Bhatt is a world-class clinician and cardiovascular researcher, and we are honored to have him join our Medical Advisory Board. His academic and clinical contributions have advanced the field significantly, and we look forward to gaining from his expert insight as we advance the ongoing Phase 3 REGULATE-PCI study of REG1."
Dr. Bhatt is currently Executive Director of Interventional Cardiovascular Programs at Brigham and Women's Hospital Heart and Vascular Center. He is also a Senior Physician at Brigham and Women's Hospital, and Professor of Medicine at Harvard Medical School. He has completed fellowships in interventional cardiology and cerebral and peripheral vascular intervention, authored or co-authored over 600 publications, and has been listed in Best Doctors in America from 2005 to the present. He was the principal or co-principal investigator for a number of late-stage international cardiovascular clinical trials.
Dr. Bhatt was a National Merit Scholar at MIT before receiving his MD from Cornell University and completing his Masters in Public Health at Harvard University. He performed his internship and residency in internal medicine at the Hospital of the University of Pennsylvania and completed his cardiovascular training at Cleveland Clinic.
ABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc. is a biopharmaceutical company focused on the development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications. Regado is pioneering the development of two-component drug systems consisting of a therapeutic aptamer and its specific active control agent. The company's lead product candidate, REG1, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen. REG1 is currently being evaluated in the REGULATE-PCI trial, a world-wide Phase 3 study enrolling 13,200 patients with acute coronary syndromes (ACS) undergoing a percutaneous coronary intervention (PCI), a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. Regado's actively controllable product candidates have the potential to improve patient outcomes, enhance the patient experience and reduce overall treatment costs. More information can be found at www.regadobio.com.
Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.
20 September 2017
19 September 2017